Volume 61, Issue 2 e202109967
Research Article

Discovery and Mechanism of Action of Small Molecule Inhibitors of Ceramidases**

Dr. Robert D. Healey

Dr. Robert D. Healey

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

These authors contributed equally to this work.

Search for more papers by this author
Dr. Essa M. Saied

Dr. Essa M. Saied

Institute for chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Str. 2, 12489 Berlin, Germany

Chemistry Department, Faculty of Science, Suez Canal University, 41522 Ismailia, Egypt

These authors contributed equally to this work.

Search for more papers by this author
Dr. Xiaojing Cong

Dr. Xiaojing Cong

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

Search for more papers by this author
Dr. Gergely Karsai

Dr. Gergely Karsai

Institute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, 8091 Switzerland

Search for more papers by this author
Ludovic Gabellier

Ludovic Gabellier

IGMM, Univ Montpellier, CNRS, Montpellier, France

Search for more papers by this author
Julie Saint-Paul

Julie Saint-Paul

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

Search for more papers by this author
Elise Del Nero

Elise Del Nero

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

Search for more papers by this author
Sylvain Jeannot

Sylvain Jeannot

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

Search for more papers by this author
Marion Drapeau

Marion Drapeau

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

Search for more papers by this author
Simon Fontanel

Simon Fontanel

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

Search for more papers by this author
Dr. Damien Maurel

Dr. Damien Maurel

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

Search for more papers by this author
Dr. Shibom Basu

Dr. Shibom Basu

EMBL Grenoble, 71 Avenue des Martyrs, CS 90181, 38042 Grenoble, France

Search for more papers by this author
Dr. Cedric Leyrat

Dr. Cedric Leyrat

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

Search for more papers by this author
Prof. Dr. Jérôme Golebiowski

Prof. Dr. Jérôme Golebiowski

Université Côte d'Azur, CNRS, Institut de Chimie de Nice UMR7272, Nice, 06108 France

Department of Brain and Cognitive Sciences, Daegu Gyeongbuk Institute of Science and Technology, Daegu, 711-873 South Korea

Search for more papers by this author
Dr. Guillaume Bossis

Dr. Guillaume Bossis

IGMM, Univ Montpellier, CNRS, Montpellier, France

Search for more papers by this author
Dr. Cherine Bechara

Dr. Cherine Bechara

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

Institut Universitaire de France (IUF), Paris, France

Search for more papers by this author
Prof. Dr. Thorsten Hornemann

Prof. Dr. Thorsten Hornemann

Institute of Clinical Chemistry, University Hospital Zurich, University of Zurich, Zurich, 8091 Switzerland

Search for more papers by this author
Prof. Dr. Christoph Arenz

Prof. Dr. Christoph Arenz

Institute for chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Str. 2, 12489 Berlin, Germany

Search for more papers by this author
Dr. Sebastien Granier

Corresponding Author

Dr. Sebastien Granier

IGF, University of Montpellier, CNRS, INSERM, Montpellier, 34094 France

Search for more papers by this author
First published: 20 October 2021
Citations: 30
**

A previous version of this manuscript has been deposited on a preprint server (https://doi.org/10.1101/2021.06.15.448479).

Graphical Abstract

Use of synthetic fluorescent ceramide molecules allows the discovery of the first selective drug-like small molecule inhibitors for alkaline ceramidase 3, an intra-membrane enzyme involved in sphingolipid metabolism in health and disease. These inhibitors represent a new paradigm for controlling lipid metabolism with drug-like small molecules targeting conformationally dynamic membrane proteins.

Abstract

Sphingolipid metabolism is tightly controlled by enzymes to regulate essential processes in human physiology. The central metabolite is ceramide, a pro-apoptotic lipid catabolized by ceramidase enzymes to produce pro-proliferative sphingosine-1-phosphate. Alkaline ceramidases are transmembrane enzymes that recently attracted attention for drug development in fatty liver diseases. However, due to their hydrophobic nature, no specific small molecule inhibitors have been reported. We present the discovery and mechanism of action of the first drug-like inhibitors of alkaline ceramidase 3 (ACER3). In particular, we chemically engineered novel fluorescent ceramide substrates enabling screening of large compound libraries and characterized enzyme:inhibitor interactions using mass spectrometry and MD simulations. In addition to revealing a new paradigm for inhibition of lipid metabolising enzymes with non-lipidic small molecules, our data lay the ground for targeting ACER3 in drug discovery efforts.

Conflict of interest

The authors declare no conflict of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.